The use of IORT at Montefiore Medical Center

Patients with early-stage, HR+/HER2-negative BC may benefit from adjuvant T-AC therapy more than from TC

Postmastectomy radiotherapy in 'intermediate-risk' breast cancer does not impact overall survival

HER3-DXd demonstrates similar efficacy compared to multi-agent chemotherapy in high-risk HR-positive/HER2-negative eBC

Post-chemo olaparib continues to improve efficacy in gBRCApv and high-risk, HER2-negative primary breast cancer

Immediate breast surgery versus deferral of surgery in women aged 70+ years with operable breast cancer

Breast conserving surgery and IORT can manage locally recurrent breast cancer

Addressing Breast Cancer Disparities in Africa

Recommendations and guidance for people living with and beyond breast cancer and colorectal cancer

The Lancet Breast Cancer Commission report: Reflections and discussion

Living Flat: Study sheds light on challenges for women of color after breast cancer surgery

CDK4/6 inhibitors and endocrine therapy in elderly female patients with advanced hormone receptor positive HER-2 negative BC